• Explore /
  • Poster
  • / Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.

Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.

Abstract Poster

Authors

Eugene Shenderov

Eugene Shenderov

Johns Hopkins University School of Medicine, Baltimore, MD

Eugene Shenderov , Angelo Demarzo , Karim Boudadi , Mohamad Allaf , Hao Wang , Carolyn Chapman , Christian Pavlovich , Trinity Bivalacqua , Tanya Skelton O'Neal , Rana Harb , Rehab Abdallah , Charles G. Drake , Drew M. Pardoll , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02923180

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5099)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5099

Abstract #

TPS5099

Poster Bd #

319b

Abstract Disclosures

Similar Posters

First Author: Eugene Shenderov

First Author: Rana R. McKay

First Author: Junlong Zhuang

Poster

2024 ASCO Genitourinary Cancers Symposium

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline <em>BRCA1/2</em> mutations.

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.

First Author: Heather H. Cheng